Oral Iloprost for the Prevention of Lung Cancer In Former Smokers
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This phase IIb trial tests whether oral iloprost works in preventing lung cancer
(chemoprevention) in former smokers. Oral iloprost has previously been shown to reduce
abnormal lung cells in former smokers, suggesting a clinically significant impact on lung
cancer risk. The use of oral iloprost may help keep cancer from forming and reduce abnormal
cells in the lung in order to lower the risk of developing lung cancer in former smokers.